Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Language menu
  5. Go to Help menu
  6. Go to modules
  7. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 
 

Welcome to Sanofi
in Hong-Kong

 

Committed to discovering, developing and distributing therapeutic solutions to improve the lives of everyone, Sanofi is a leading global pharmaceutical company. Number 1 in Europe, the Group is present in more than 100 countries and is growing rapidly. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY) and has one of the largest market capitalizations in Paris.

     
     
     

    Content :

    Contact us

    Sanofi

    Units 706-710, Level 7,
    Core C, Cyberport 3,
    100 Cyberport Road,
    Hong Kong

    Tel.: (852) 2506 8333
    Fax: (852) 2506 2537

    Sanofi Pasteur
    Sanofi TV

    Welcome to Sanofi in Hong Kong

    Every year, the Group spent about one sixth (15%) of its sales revenue into Research & Development. In 2006, the Group invested 4.4 billion euros out of its net sales of 28.4 billion euros.

    With a portfolio containing a wide range of innovative vaccines and medicines, sanofi-aventis excels in the areas of Thrombosis, Diabetes, Cardiovascular diseases, Oncology, disorders of the Central Nervous System, Vaccines and Internal Medicine.

    Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billion doses of vaccine in 2006, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases.

    The Company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us.

    If you would like more information than what we can provide here on any aspect of our work, please contact us.

     
    Happy company
    Caring company - 5 consecutive years
    1st Manpower Developer Award
    Logo Corporate Award 2016
    HSBC Living Business

    News

    March 23, 2016

    Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy

    March 16, 2016

    Sanofi and DiCE Molecules Announce Research Collaboration to Discover Potential Therapeutics Based on Unique Small Molecule Discovery Platform

    March 16, 2016

    Sanofi and Regeneron Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent® (alirocumab) Injection and Will Appeal

    March 11, 2016

    Sanofi and Regeneron Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis

     

    Career opportunities